2023-04-27 カリフォルニア大学サンタバーバラ校(UCSB)
新しい検査方法は、抗生物質の開発、検査、処方方法を改善する可能性があります。この研究は、現在利用可能な抗生物質の処方と使用を最適化し、新しい抗生物質を発見する取り組みを強化することで、細菌耐性の戦いに重要な意義があります。
<関連情報>
- https://www.news.ucsb.edu/2023/021022/new-test-reveals-existing-antibiotics-hiding-plain-sight-pharmacy-shelves-can-cure
- https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00133-7
抗菌薬耐性評価のための診断精度を高めたFDA認可の抗生物質の再評価 Re-evaluation of FDA-approved antibiotics with increased diagnostic accuracy for assessment of antimicrobial resistance
Douglas M. Heithoff,Lucien Barnes V,Scott P. Mahan,Jeffrey C. Fried,Lynn N. Fitzgibbons,John K. House,Michael J. Mahan
Cell Reports Medicine Published:April 27, 2023
DOI:https://doi.org/10.1016/j.xcrm.2023.101023
Highlights
•Antibiotic testing in cell culture medium improves prediction of clinical outcome
•Antibiotics rejected by standard testing cure drug-resistant infections
•Ineffective antibiotics are identified despite indicated use by standard testing
Summary
Accurate assessment of antibiotic susceptibility is critical for treatment of antimicrobial resistant (AMR) infections. Here, we examine whether antimicrobial susceptibility testing in media more physiologically representative of in vivo conditions improves prediction of clinical outcome relative to standard bacteriologic medium. This analysis reveals that ∼15% of minimum inhibitory concentration (MIC) values obtained in physiologic media predicted a change in susceptibility that crossed a clinical breakpoint used to categorize patient isolates as susceptible or resistant. The activities of antibiotics having discrepant results in different media were evaluated in murine sepsis models. Testing in cell culture medium improves the accuracy by which MIC assays predict in vivo efficacy. This analysis identifies several antibiotics for treatment of AMR infections that standard testing failed to identify and those that are ineffective despite indicated use by standard testing. Methods with increased diagnostic accuracy mitigate the AMR crisis via utilizing existing agents and optimizing drug discovery.
